90%Confidence
0Views
FDASource
2026-03-19Date
Summary
Semaglutide API recall due to incomplete validation processes creates significant supply chain risks for compounding pharmacies and weight loss clinics relying on this popular GLP-1 agonist. The Chinese manufacturer's failure to complete basic validations suggests broader quality concerns for imported active pharmaceutical ingredients.
Actionable: Immediately audit all products containing Semaglutide API from Chinese suppliers and secure alternative validated sources.
AI Confidence: 90%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now